(E)-3-(2-(pyridin-3-yl)vinyl)-1H-indazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (E)-3-(2-(pyridin-3-yl)vinyl)-1H-indazole
• 英文别名: (E)-3-[2-(pyridin-3-yl)vinyl]-1H-indazole；(E)-3-[2-(3-Pyridyl)vinyl]-1H-indazole；3-[(E)-2-pyridin-3-ylethenyl]-1H-indazole
• 化学式: C₁₄H₁₁N₃
• 分子量: 221.261
• InChiKey: HWDBUEBDESOCBK-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-3-(2-(pyridin-3-yl)vinyl)-1H-indazole 在 硫酸 、 硝酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 以45%的产率得到(E)-5-Nitro-3-[2-(pyridin-3-yl)-vinyl]-1H-indazole
  参考文献：
  名称：

  JNK INHIBITOR

  摘要：

  本发明提供了一种JNK抑制剂，其包括一种以Formula (I)所代表的吲唑衍生物作为活性成分 [其中R1代表取代或未取代的芳基或类似物，R2代表氢原子，NR3R4（其中R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷酰基或类似物）、羧基、较低烯基或类似物]或其药用可接受的盐。

  公开号：

  EP1582211A1
• 作为产物：
  描述：

  3-吡啶甲醛 、 [(1H-indazol-3-yl)methyl]triphenylphosphonium iodide 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以50%的产率得到(E)-3-(2-(pyridin-3-yl)vinyl)-1H-indazole
  参考文献：
  名称：

  JNK INHIBITOR

  摘要：

  本发明提供了一种JNK抑制剂，其包括一种以Formula (I)所代表的吲唑衍生物作为活性成分 [其中R1代表取代或未取代的芳基或类似物，R2代表氢原子，NR3R4（其中R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷酰基或类似物）、羧基、较低烯基或类似物]或其药用可接受的盐。

  公开号：

  EP1582211A1

文献信息

• Jnk inhibitor
  申请人：Kanai Fumihiko

  公开号：US20060058366A1

  公开（公告）日：2006-03-16

  The present invention provides a JNK inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I) [wherein R 1 represents substituted or unsubstituted aryl or the like and R 2 represents a hydrogen atom, NR 3 R 4 (wherein R 3 and R 4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkanoyl or the like), carboxy, lower alkenyl or the like] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种JNK抑制剂，其包括以下式(I)所表示的吲唑衍生物作为活性成分：[式中，R1代表取代或未取代的芳基或类似物，R2代表氢原子，NR3R4（其中R3和R4可以相同也可以不同，每个代表氢原子，取代或未取代的较低烷酰基或类似物），羧基，较低的烯基或类似物]或其药学上可接受的盐。
• Protein kinase inhibitors
  申请人：Shiotsu Yukimasa

  公开号：US20060281789A1

  公开（公告）日：2006-12-14

  The present invention provides a protein kinase inhibitor (excluding c-Jun N-terminal kinase inhibitor) which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof.

  本发明提供了一种蛋白激酶抑制剂（不包括c-Jun N末端激酶抑制剂），其包括以下作为活性成分的吲唑衍生物（式（I）所表示，其中R1代表取代或未取代的芳基或取代或未取代的杂环基）或其药学上可接受的盐。
• PROTEIN KINASE INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1650194A1

  公开（公告）日：2006-04-26

  The present invention provides a protein kinase inhibitor (excluding c-Jun N-terminal kinase inhibitor) which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof.

  本发明提供了一种蛋白激酶抑制剂（不包括 c-Jun N-末端激酶抑制剂），其活性成分包括由式（I）表示的吲唑衍生物 (其中 R1 代表取代或未取代的芳基或取代或未取代的杂环基团）或其药学上可接受的盐。
• Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
  作者：Eduard Dolušić、Pierre Larrieu、Laurence Moineaux、Vincent Stroobant、Luc Pilotte、Didier Colau、Lionel Pochet、Benoît Van den Eynde、Bernard Masereel、Johan Wouters、Raphaël Frédérick

  DOI：10.1021/jm2006782

  日期：2011.8.11

  Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance. IDO inhibition is thus an active area of research in drug development. Recently, our group has shown that tryptophan 2,3-dioxygenase (TDO), an unrelated hepatic enzyme also catalyzing the first step of tryptophan degradation, is also expressed in many tumors and that this expression prevents tumor rejection by locally depleting tryptophan. Herein, we report a structure- activity study on a series of 3-(2-(pyridyl)ethenyl)indoles. More than 70 novel derivatives were synthesized, and their TDO inhibitory potency was evaluated. The rationalization of the structure-activity relationships (SARs) revealed essential features to attain high TDO inhibition and notably a dense H-bond network mainly involving His(55) and Thr(254) residues. Our study led to the identification of a very promising compound (58) displaying good TDO inhibition (K-i = 5.5 mu M), high selectivity, and good oral bioavailability. Indeed, 58 was chosen for preclinical evaluation.
• Therapeutic Methods for Type I Diabetes
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20150313881A1

  公开（公告）日：2015-11-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.